Imvotamab is a T cell engaging antibody that targets CD20 and CD3 proteins. IGM Biosciences was evaluating it in three trials, the third being a treatment for myositis, a rare autoimmune disease that ...

The biotech will stop developing two drugs and lay off much of its staff after its lead therapy wasn’t as potent in early testing as the company expected.

Wedbush restated their neutral rating on shares of IGM Biosciences (NASDAQ:IGMS – Free Report) in a report issued on Friday ...

Royal Bank of Canada lowered shares of IGM Biosciences (NASDAQ:IGMS – Free Report) from an outperform rating to a sector ...

and viral antigens such as the NS1 protein when the patient has viremia (high levels of the dengue virus in the blood). IgM and IgG antibodies against the dengue virus can be detected in most ...

High serum CXCL13 levels are predictive of treatment failure with first-line MTX among patients with early RA.